BIOMAT Database Logo BIOMAT Database Logo

Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. 2019

Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, No. 22 Qixiangtai Rd, Heping Dist, Tianjin, 300070, People's Republic of China.

SHP2 phosphatase, encoded by the PTPN11 gene, is a non-receptor PTP, which plays an important role in growth factor, cytokine, integrin, hormone signaling pathways, and regulates cellular responses, such as proliferation, differentiation, adhesion migration and apoptosis. Many studies have reported that upregulation of SHP2 expression is closely related to human cancer, such as breast cancer, liver cancer and gastric cancer. Hence, SHP2 has become a promising target for cancer immunotherapy. In this paper, we reported the identification of compound 1 as SHP2 inhibitor. Fragment-based ligand design, De novo design, ADMET and Molecular docking were performed to explore potential selective SHP2 allosteric inhibitors based on SHP836. The results of docking studies indicated that the selected compounds had higher selective SHP2 inhibition than existing inhibitors. Compound 1 was found to have a novel selectivity against SHP2 with an in vitro enzyme activity IC50 value of 9.97 μM. Fluorescence titration experiment confirmed that compound 1 directly bound to SHP2. Furthermore, the results of binding free energies demonstrated that electrostatic energy was the primary factor in elucidating the mechanism of SHP2 inhibition. Dynamic cross correlation studies also supported the results of docking and molecular dynamics simulation. This series of analyses provided important structural features for designing new selective SHP2 inhibitors as potential drugs and promising candidates for pre-clinical pharmacological investigations.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D054592 Protein Tyrosine Phosphatase, Non-Receptor Type 11 A subtype of non-receptor protein tyrosine phosphatases that contain two SRC HOMOLOGY DOMAINS. Mutations in the gene for protein tyrosine phosphatase, non-receptor type 11 are associated with NOONAN SYNDROME. Phosphotyrosine Phosphatase Syp,Protein Tyrosine Phosphatase PTP3,Protein-Tyrosine-Phosphatase 2C,SHP-2 Protein-Tyrosine Phosphatase,SHP2 Phosphatase,SHPTP2,Shp-2 Tyrosine Phosphatase,Phosphatase, SHP2,Protein Tyrosine Phosphatase 2C,Protein Tyrosine Phosphatase, Non Receptor Type 11,Shp 2 Tyrosine Phosphatase,Tyrosine Phosphatase, Shp-2

Related Publications

Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
July 2020, Bioorganic chemistry,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
October 2021, Chemistry (Weinheim an der Bergstrasse, Germany),
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
February 2022, European journal of medicinal chemistry,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
November 2006, Bioorganic & medicinal chemistry letters,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
January 2001, Drug design and discovery,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi.
February 2003, Journal of medicinal chemistry,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
September 2015, Bioorganic & medicinal chemistry letters,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors.
July 2014, Organic & biomolecular chemistry,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
August 2009, Bioorganic & medicinal chemistry letters,
Wen-Shan Liu, and Wen-Yan Jin, and Liang Zhou, and Xing-Hua Lu, and Wei-Ya Li, and Ying Ma, and Run-Ling Wang
Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
January 2012, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!